Healthcare
Live Price
Offline$1.04
+0.97% today
1Y Change
-27.89%
Window
Jun 26, 2025 → Jun 18, 2026
Coverage: 246 bars · Jun 26, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Cardiol Therapeutics Inc. (CRDL) is a Healthcare stock with a market cap of $200.00M. The stock last traded around $1.04 and down 27.9% across the available one-year price window (Jun 26, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +23.5%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +23.5%, free cash flow +4.8% with operating margin 0.0% and ROIC -190.6%. Stock Foundry combines CRDL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CRDL
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CRDL Max Drawdown
-39.87%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for CRDL and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
-100.0% YoY
FY Net Income
-$16.2M
+35.2% YoY
Free Cash Flow
-$9.2M
+61.1% YoY
Revenue Growth
+0.0%
EPS Growth
+23.5%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
CAD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 62K | 0 |
| Gross Profit | 0 | -187K | -162K | -112K | -180K |
| Operating Income | -40M | -22M | -30M | -31M | -16M |
| EBITDA | -40M | -21M | -23M | -25M | -16M |
| Net Income | -37M | -21M | -23M | -25M | -16M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CAD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 31M | 35M | 44M | 84M | 14M |
| Total Assets | 32M | 37M | 46M | 88M | 16M |
| Total Liabilities | 7M | 8M | 7M | 12M | 3M |
| Shareholder Equity | 25M | 28M | 39M | 76M | 13M |
| Total Debt | 159K | 174K | 54K | 118K | 157K |
| Net Debt | -30M | -35M | -44M | -84M | -14M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
9M
+61.2% YoY
Capital Expenditures
41K
-214.4% YoY
Free Cash Flow
9M
+61.1% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-238.0%
Debt / Equity
0.01x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.